NCT05059977View on ClinicalTrials.gov

A Study of TAK-881 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 12, 2021

Primary Completion Date

April 12, 2022

Study Completion Date

April 12, 2022

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

TAK-881

Participants will receive subcutaneous infusion of TAK-881 on Day 1.

Trial Locations (1)

33014

Clinical Pharmacology of Miami, Hialeah

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
collaborator

Takeda Development Center Americas, Inc.

INDUSTRY

collaborator

Baxalta Innovations GmbH, now part of Shire

INDUSTRY

lead

Takeda

INDUSTRY